Literature DB >> 28748346

Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.

Jacky D Luiten1,2, Adri C Voogd3,4, Ernest J T Luiten2, Lucien E M Duijm5,6.   

Abstract

PURPOSE: In a biennial screening mammography programme, we analysed the trends in incidence of screen-detected DCIS and invasive breast cancers in the era of screen-film mammography (SFM) screening, the period of the transition to full-field digital mammography (FFDM) screening and the period of FFDM screening. We also investigated a possible association between the incidence and grading of screen-detected DCIS and invasive breast cancer.
METHODS: In the southern part of the Netherlands, FFDM screening gradually replaced SFM screening between May 2009 and April 2010. We included a consecutive series of 484, 422 screens obtained between July 2005 and July 2015 and divided these screens into three groups; SFM-only cohort, transition cohort and FFDM-only cohort.
RESULTS: A total of 3059 referred women were diagnosed with DCIS (n = 623) or invasive breast cancer (n = 2436). The majority of DCIS were high-grade (48.2%), whereas the majority of the invasive breast cancers were low-grade (45.4%) or intermediate-grade (41.6%). The cancer detection rate (CDR) per 1000 screened women showed the same distribution by grade in both groups. The transition to FFDM was characterised by an increased overall detection rate of invasive cancers.
CONCLUSIONS: Screening mammography detects mostly high-grade DCIS and low- or intermediate-grade invasive cancers. The grade distribution as well as the CDR in the years after the introduction of FFDM remained stable compared to the era of SFM screening. By diagnosing and treating high-grade DCIS, which otherwise may develop into high-grade invasive carcinoma, our findings provide new evidence for the beneficial value of screening mammography programmes.

Entities:  

Keywords:  Breast cancer screening; Ductal carcinoma in situ; Invasive breast cancer; Tumour grade

Mesh:

Year:  2017        PMID: 28748346     DOI: 10.1007/s10549-017-4412-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup.

Authors:  Julius Emons; Peter A Fasching; Marius Wunderle; Felix Heindl; Jens Rieger; Florian Horn; Georg Pelzer; Andre Ritter; Thomas Weber; Marcus Radicke; Iris Polifka; David L Wachter; Evelyn Wenkel; Thilo Michel; Michael Uder; Arndt Hartmann; Gisela Anton; Matthias W Beckmann; Rüdiger Schulz-Wendtland; Sebastian M Jud
Journal:  Ther Adv Med Oncol       Date:  2020-09-18       Impact factor: 8.168

2.  Optimal Screening in Breast Cancer Survivors With Dense Breasts on Mammography.

Authors:  Habib Rahbar; Janie M Lee; Christoph I Lee
Journal:  J Clin Oncol       Date:  2020-07-24       Impact factor: 50.717

3.  Pure Ductal Carcinoma In Situ of the Breast: Analysis of 270 Consecutive Patients Treated in a 9-Year Period.

Authors:  Corrado Chiappa; Alice Bonetti; Giulio Jad Jaber; Valentina De Berardinis; Veronica Bianchi; Francesca Rovera
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

4.  Radiopaque tissue transfer and X-ray system versus standard specimen radiography for intraoperative margin assessment in breast-conserving surgery: randomized clinical trial.

Authors:  Angrit Stachs; Julia Bollmann; Annett Martin; Johannes Stubert; Toralf Reimer; Bernd Gerber; Steffi Hartmann
Journal:  BJS Open       Date:  2022-07-07

5.  Magnetic resonance imaging based 3-dimensional printed breast surgical guide for breast-conserving surgery in ductal carcinoma in situ: a clinical trial.

Authors:  Zhen-Yu Wu; Aisha Alzuhair; Heejeong Kim; Jong Won Lee; Il Yong Chung; Jisun Kim; Sae Byul Lee; Byung Ho Son; Gyungyub Gong; Hak Hee Kim; Joon Beom Seo; Sei Hyun Ahn; Namkug Kim; BeomSeok Ko
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.